Oesophageal Adenocarcinoma
14
3
4
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (14)
Will a Pre-therapy Exercise Intervention Improve the Outcomes of Patients With Advanced Oesophageal Cancer?
Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection
AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Evaluation of Seismocardiography(SCG) for Assessing Fitness and Predicting Outcomes in Oesophageal Cancer Surgery
Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy
Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery
Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy
M6620 Plus Standard Treatment in Oesophageal and Other Cancer
Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer
Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma
Prehabilitation of Patients With oEsophageal Malignancy Undergoing Peri-operative Treatment
Exercise Prior to Oesophagectomy
Effects of Chemotherapy on Muscle Mass and Exercise Performance in Patients With Oesophageal Cancer.